Ligand Pharmaceuticals (LGND) Current Leases (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Current Leases of $1.1 million for Q1 2026, down 0.64% sequentially from $1.1 million in Q4 2025, and up 26.66% YoY from $859000.0 in Q1 2025.
Ligand Pharmaceuticals (LGND) Current Leases (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Current Leases for 15 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Current Leases rose 26.66% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 26.66% YoY) and the FY2025 annual result came in at $1.1 million, down 13.51% from the prior year.
- Current Leases declined to $1.1 million in Q1 2026 per LGND's latest filing, from $1.1 million in the prior quarter.
- Over five years, Current Leases peaked at $2.3 million in Q3 2022 and troughed at $24000.0 in Q2 2025.
- A 5-year average of $787235.3 and a median of $859000.0 in 2025 frame the typical range for Current Leases.
- The widest YoY moves for Current Leases: up 5111.11% in 2022, down 99.04% in 2022.
- Over 5 years, Current Leases stood at $670000.0 in 2022, then plunged by 39.85% to $403000.0 in 2023, then surged by 214.14% to $1.3 million in 2024, then decreased by 13.51% to $1.1 million in 2025, then fell by 0.64% to $1.1 million in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $1.1 million, $1.1 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 1.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.08 Mn |
| Mar 31, 2026 | 1.09 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 24,000.00 |
| Mar 31, 2025 | 859,000.00 |
| Dec 31, 2024 | 1.27 Mn |
| Sep 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 1.16 Mn |
| Mar 31, 2024 | 1.00 Mn |
| Dec 31, 2023 | 403,000.00 |
| Sep 30, 2023 | 497,000.00 |
| Jun 30, 2023 | 680,000.00 |
| Mar 31, 2023 | 43,000.00 |
| Dec 31, 2022 | 670,000.00 |
| Sep 30, 2022 | 2.35 Mn |
| Jun 30, 2022 | 50,000.00 |
| Mar 31, 2022 | 52,000.00 |
| Dec 31, 2021 | 45,000.00 |
| Sep 30, 2021 | 45,000.00 |